|
1
|
Yuasa Y: Control of gut differentiation
and intestinal-type gastric carcinogenesis. Nat Rev Cancer.
3:592–600. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Panani AD: Cytogenetic and molecular
aspects of gastric cancer: Clinical implications. Cancer Lett.
266:99–115. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coburn N, Cosby R, Klein L, Knight G,
Malthaner R, Mamazza J, Mercer CD and Ringash J: Staging and
surgical approaches in gastric cancer: A systematic review. Cancer
Treat Rev. 63:104–115. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Luo X, Yang B and Nattel S: MicroRNAs and
atrial fibrillation: Mechanisms and translational potential. Nat
Rev Cardiol. 12:80–90. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Frampton AE, Castellano L, Colombo T,
Giovannetti E, Krell J, Jacob J, Pellegrino L, Roca-Alonso L, Funel
N, Gall TM, et al: MicroRNAs cooperatively inhibit a network of
tumor suppressor genes to promote pancreatic tumor growth and
progression. Gastroenterology. 146:268–277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Emmrich S, Katsman-Kuipers JE, Henke K,
Khatib ME, Jammal R, Engeland F, Dasci F, Zwaan CM, den Boer ML,
Verboon L, et al: miR-9 is a tumor suppressor in pediatric AML with
t(8;21). Leukemia. 28:1022–1032. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang HH, Gu GL, Zhang XY, Li FZ, Ding L,
Fan Q, Wu R, Shi W, Wang XY, Chen L, et al: Primary analysis and
screening of microRNAs in gastric cancer side population cells.
World J Gastroenterol. 21:3519–3526. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen Z, Saad R, Jia P, Peng D, Zhu S,
Washington MK, Zhao Z, Xu Z and El-Rifai W: Gastric adenocarcinoma
has a unique microRNA signature not present in esophageal
adenocarcinoma. Cancer. 119:1985–1993. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guo B, Liu L, Yao J, Ma R, Chang D, Li Z,
Song T and Huang C: miR-338-3p suppresses gastric cancer
progression through a PTEN-AKT axis by targeting P-REX2a. Mol
Cancer Res. 12:313–321. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang F, Li T, Zhang B, Li H, Wu Q, Yang L,
Nie Y, Wu K, Shi Y and Fan D: MicroRNA-19a/b regulates multidrug
resistance in human gastric cancer cells by targeting PTEN. Biochem
Biophys Res Commun. 434:688–694. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Si Y, Zhang H, Ning T, Bai M, Wang Y, Yang
H, Wang X, Li J, Ying G and Ba Y: miR-26a/b inhibit tumor growth
and angiogenesis by targeting the HGF-VEGF axis in gastric
carcinoma. Cell Physiol Biochem. 42:1670–1683. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Lu Q and Cai X: MicroRNA-106a
induces multidrug resistance in gastric cancer by targeting RUNX3.
FEBS Lett. 587:3069–3075. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tsujiura M, Komatsu S, Ichikawa D,
Shiozaki A, Konishi H, Takeshita H, Moriumura R, Nagata H,
Kawaguchi T, Hirajima S, et al: Circulating miR-18a in plasma
contributes to cancer detection and monitoring in patients with
gastric cancer. Gastric Cancer. 18:271–279. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ren C, Wang W, Han C, Chen H, Fu D, Luo Y,
Yao H, Wang D, Ma L, Zhou L, et al: Expression and prognostic value
of miR-92a in patients with gastric cancer. Tumour Biol.
37:9483–9491. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thomson DW, Bracken CP and Goodall GJ:
Experimental strategies for microRNA target identification. Nucleic
Acids Res. 39:6845–6853. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pernot S, Voron T, Perkins G,
Lagorce-Pages C, Berger A and Taieb J: Signet-ring cell carcinoma
of the stomach: Impact on prognosis and specific therapeutic
challenge. World J Gastroenterol. 21:11428–11438. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Singh SS, Yap WN, Arfuso F, Kar S, Wang C,
Cai W, Dharmarajan AM, Sethi G and Kumar AP: Targeting the PI3K/Akt
signaling pathway in gastric carcinoma: A reality for personalized
medicine? World J Gastroenterol. 21:12261–12273. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Okugawa Y, Toiyama Y, Hur K, Toden S,
Saigusa S, Tanaka K, Inoue Y, Mohri Y, Kusunoki M, Boland CR and
Goel A: Metastasis-associated long non-coding RNA drives gastric
cancer development and promotes peritoneal metastasis.
Carcinogenesis. 35:2731–2739. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Harapan H, Fitra F, Ichsan I, Mulyadi M,
Miotto P, Hasan NA, Calado M and Cirillo DM: The roles of microRNAs
on tuberculosis infection: Meaning or myth? Tuberculosis (Edinb).
93:596–605. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu W, Takanashi M, Borjigin N, Ohno SI,
Fujita K, Hoshino S, Osaka Y, Tsuchida A and Kuroda M: MicroRNA-18a
modulates STAT3 activity through negative regulation of PIAS3
during gastric adenocarcinogenesis. Br J Cancer. 108:653–661. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu P, Zhang J, Zhu J, Shi J, Zhu Q and
Gao Y: miR-429 induces gastric carcinoma cell apoptosis through
Bcl-2. Cell Physiol Biochem. 37:1572–1580. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou C, Shen L, Mao L, Wang B, Li Y and Yu
H: miR-92a is upregulated in cervical cancer and promotes cell
proliferation and invasion by targeting FBXW7. Biochem Biophys Res
Commun. 458:63–69. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ke TW, Wei PL, Yeh KT, Chen WT and Cheng
YW: miR-92a promotes cell metastasis of colorectal cancer through
PTEN-mediated PI3K/AKT pathway. Ann Surg Oncol. 22:2649–2655. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang G, Zhou H, Xiao H, Liu Z, Tian H and
Zhou T: MicroRNA-92a functions as an oncogene in colorectal cancer
by targeting PTEN. Dig Dis Sci. 59:98–107. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen ZL, Zhao XH, Wang JW, Li BZ, Wang Z,
Sun J, Tan FW, Ding DP, Xu XH, Zhou F, et al: MicroRNA-92a promotes
lymph node metastasis of human esophageal squamous cell carcinoma
via E-cadherin. J Biol Chem. 286:10725–10734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu X, Zhu S, Tao Z and Ye S: High
circulating miR-18a, miR-20a, and miR-92a expression correlates
with poor prognosis in patients with non-small cell lung cancer.
Cancer Med. 7:21–31. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ranade AR, Cherba D, Sridhar S, Richardson
P, Webb C, Paripati A, Bowles B and Weiss GJ: MicroRNA 92a-2*: A
biomarker predictive for chemoresistance and prognostic for
survival in patients with small cell lung cancer. J Thorac Oncol.
5:1273–1278. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ludwig S, Klitzsch A and Baniahmad A: The
ING tumor suppressors in cellular senescence and chromatin. Cell
Biosci. 1:252011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Unoki M, Kumamoto K, Robles AI, Shen JC,
Zheng ZM and Harris CC: A novel ING2 isoform, ING2b, synergizes
with ING2a to prevent cell cycle arrest and apoptosis. FEBS Lett.
582:3868–3874. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Y, Wang J and Li G: Leucine
zipper-like domain is required for tumor suppressor ING2-mediated
nucleotide excision repair and apoptosis. FEBS Lett. 580:3787–3793.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pedeux R, Sengupta S, Shen JC, Demidov ON,
Saito S, Onogi H, Kumamoto K, Wincovitch S, Garfield SH, McMenamin
M, et al: ING2 regulates the onset of replicative senescence by
induction of p300-dependent p53 acetylation. Mol Cell Biol.
25:6639–6648. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shi X, Hong T, Walter KL, Ewalt M,
Michishita E, Hung T, Carney D, Peña P, Lan F, Kaadige MR, et al:
ING2 PHD domain links histone H3 lysine 4 methylation to active
gene repression. Nature. 442:96–99. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bua DJ, Martin GM, Binda O and Gozani O:
Nuclear phosphatidylinositol-5-phosphate regulates ING2 stability
at discrete chromatin targets in response to DNA damage. Sci Rep.
3:21372013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Han XR, Bai XZ, Sun Y and Yang Y: Nuclear
ING2 expression is reduced in osteosarcoma. Oncol Rep.
32:1967–1972. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ythier D, Larrieu D, Binet R, Binda O,
Brambilla C, Gazzeri S and Pedeux R: Sumoylation of ING2 regulates
the transcription mediated by Sin3A. Oncogene. 29:5946–5956. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sarker KP, Kataoka H, Chan A, Netherton
SJ, Pot I, Huynh MA, Feng X, Bonni A, Riabowol K and Bonni S: ING2
as a novel mediator of transforming growth factor-beta-dependent
responses in epithelial cells. J Biol Chem. 283:13269–13279. 2008.
View Article : Google Scholar : PubMed/NCBI
|
